21. September 2009 07:24
Reportlinker.com announces that a new market research report is available in its catalogue.
Reportlinker Adds Bristol-Myers Squibb Co.: PharmaVitae Profile
http://www.reportlinker.com/p0148175/Reportlinker-Adds-Bristol-Myers-Squibb-Co-PharmaVitae-Profile.html
Introduction
This analysis examines the historical and forecast performance for BMS in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
- Benchmark Bristol-Myers Squibb's performance against key rivals in the ethical pharmaceutical sector
- Assess how BMS is exploring the fast-growth oncology and immunology disease markets to drive long-term sales in the face of blockbuster patent expiry
- Investigate the strength of BMS's pipeline, its product collaborations with AstraZeneca and Pfizer and the recent acquisition of Medarex.
http://www.reportlinker.com
3eecd1a7-e9f1-4720-917d-d5be8794ec2d|0|.0
Posted in: Business / Finance
Tags: Abilify, Antipsychotic, Apixaban, Hepatitis B, Immunology, Nervous System, Oncology, Onglyza, Pfizer, Plavix, Sprycel, Truvada, Zyprexa
News-Medical.Net provides this medical information service in accordance
with these
terms and conditions.
Please note that medical information found
on this website is designed to support, not to replace the relationship
between patient and physician/doctor and the medical advice they may provide.
Subscribe